Related Experiment Video
Updated: Jul 8, 2026
07:17
Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
CD117 immunoreactivity in atypical fibroxanthoma
Rahel A Mathew1, Scott M Schlauder, Kenneth B Calder
1Department of Pathology, University of South Florida College of Medicine, Tempa, FL 33612, USA.
The American Journal of Dermatopathology
|January 24, 2008
Summary
Atypical fibroxanthoma (AFX), a skin neoplasm, frequently expresses CD117 (c-kit receptor). This finding suggests CD117 is a sensitive diagnostic marker for AFX, aiding in its identification.
Area of Science:
- Dermatopathology
- Oncology
- Molecular Biology
Background:
- Atypical fibroxanthoma (AFX) is a skin neoplasm often found on sun-damaged skin in the elderly.
- While typically considered benign, AFX can recur locally and metastasize distantly.
- The pathogenic mechanisms underlying AFX development require further investigation.
Purpose of the Study:
- To investigate the role of CD117 (c-kit receptor) in the pathogenesis of Atypical fibroxanthoma.
- To determine the prevalence and significance of CD117 expression in AFX.
- To evaluate CD117 as a potential diagnostic marker for AFX.
Main Methods:
- Immunohistochemical analysis was performed on 16 cases of Atypical fibroxanthoma.
- The expression of CD117 (c-kit receptor) was assessed in tumor cells.
- The percentage of CD117-positive cells within each tumor was quantified.
Main Results:
- CD117 expression was detected in 15 out of 16 AFX cases, representing a 94% positivity rate.
- Approximately 30% of tumor cells exhibited CD117 expression across all evaluated cases.
- CD117 was identified as a highly sensitive marker for Atypical fibroxanthoma.
Conclusions:
- CD117 (c-kit receptor) is frequently expressed in Atypical fibroxanthoma.
- The high sensitivity of CD117 in AFX suggests its utility as a diagnostic marker.
- CD117 immunohistochemistry can serve as a valuable adjunct in the diagnosis of AFX.
